Core Viewpoint - The investment by Sunshine Nuohong in Yuanma Zhiyao highlights the growing interest and activity in the in vivo CAR-T therapy sector, which is seen as a promising alternative to traditional CAR-T therapies due to its potential for reduced costs and shorter preparation times [1][4][10]. Company Investment - On October 20, Sunshine Nuohong announced an investment of 15 million yuan (approximately 2.1 million USD) in Yuanma Zhiyao, acquiring an 8.2% stake in the company [4][5]. - Yuanma Zhiyao, established in June 2023, focuses on the innovative research and development of circular mRNA in vivo CAR-T therapies and is currently in the early stages of pipeline development [4][5]. Industry Trends - The in vivo CAR-T therapy field has seen increased investment and collaboration from major pharmaceutical companies, including AstraZeneca, AbbVie, and Bristol-Myers Squibb, indicating a trend towards this innovative treatment approach [8][9]. - The traditional CAR-T therapy process is lengthy and costly, typically taking 3-4 weeks and costing over 1 million yuan (approximately 140,000 USD), which limits its accessibility [5][10]. Advantages of In Vivo CAR-T - In vivo CAR-T therapy offers significant advantages over traditional methods, including a reduced preparation time of 2-3 days and potential cost reductions to below 50,000 USD per treatment [10][12]. - The technology allows for a more streamlined process, eliminating the need for personalized quality control and GMP cell factories, thus making it more accessible to patients [10][12]. Challenges Ahead - Despite its potential, in vivo CAR-T therapy faces challenges such as delivery efficiency, dosage control, and long-term safety, which require further clinical validation [11][12]. - The complexity of the human body poses risks in ensuring that the viral or LNP carriers deliver the intended effects without adverse reactions [11][12]. Future Outlook - Industry experts predict that within 3-5 years, the first in vivo CAR-T product may receive approval, potentially coexisting with traditional CAR-T therapies and becoming a mainstream treatment option [12][13]. - The ongoing advancements in research and clinical trials are expected to address current challenges, making in vivo CAR-T therapies more accessible and affordable for patients in the near future [13].